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Abstract
Neuroblastoma (NBL) is the most common malignant
disease of infancy, and children with bone metastasis
have a mortality rate greater than 90%. Two major
classes of proteins, integrins and growth factors,
regulate the metastatic process. We have previously
shown that tumorigenic NBL cells express higher
levels of the type I insulin-like growth factor receptor
(IGF-IR) and that B1 integrin expression is inversely
proportional to tumorigenic potential in NBL. In the
current study, we analyze the effect of B1 integrin
and IGF-IR on NBL cell attachment and migration.
Nontumorigenic S-cells express high levels of B1
integrin, whereas tumorigenic N-cells express little
B1 integrin. Alterations in B1 integrin are due to regu-
lation at the protein level, as translation is decreased
in N-type cells. Moreover, inhibition of protein syn-
thesis shows that B1 integrin is degraded more slowly
in S-type cells (SHEP) than in N-type cells (SH-SY5Y
and IMR32). Inhibition of A5B1 integrin prevents SHEP
(but not SH-SY5Y or IMR32) cell attachment to fibro-
nectin and increases SHEP cell migration. Increases in
IGF-IR decrease B1 integrin expression, and enhance
SHEP cell migration, potentially through increased
expression of AvB3. These data suggest that specific
classes of integrins in concert with IGF-IR regulate
NBL attachment and migration.
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Introduction
Neuroblastoma (NBL) accounts for approximately 8% to
10% of all childhood cancers and is the most common
malignant disease of infancy. NBL remains an understudied
area, despite the fact there is a 90% mortality rate for
children with NBL with bony metastatic disease [1–3].
Our laboratory has studied the role of insulin-like growth
factors (IGFs) I and II, and the type I insulin-like growth
factor receptor (IGF-IR) in NBL tumor biology. We have
reported that IGF-I or IGF-II coupled to IGF-IR promotes
growth of human NBL cells [4–9], prevents NBL apoptosis
[10–15], enhances NBL cell motility [16,17], and increases
NBL invasion [18]. Highly tumorigenic NBL cells express
increased levels of IGF-IR [19] and inhibition of IGF-IR expres-
sion using antisense strategies inhibits tumor growth and
induces regression of NBL tumors in mice [20]. These data
suggest that there are distinct ‘‘biologic signatures’’ for low-
grade and high-grade NBL defined, in part, by IGF-IR expres-
sion and signaling.
Our recent data suggest that another family of proteins, the
integrins, is also essential in defining the ‘‘biologic signatures’’
of high-grade and low-grade NBL [21]. The integrins are
heterodimeric glycoprotein cell surface receptors comprised
of a and h subunits that mediate cell–cell and cell–extracel-
lular matrix (ECM) interactions. These interactions signal mul-
tiple cellular responses including adhesion and migration [22],
and are known to participate in many aspects of tumorigenesis
[23]. Primary NBL tumors with a good prognosis express
several h1 integrin heterodimers, whereas NBL tumors with a
poor prognosis lack integrins with h1 subunits [24]. In vitro, the
absence of h1 integrin in NBL cell lines causes tumor cell
detachment, whereas the expression of h1 integrin protein
correlates with attached cells [25]. In parallel, low-grade differ-
entiated NBL cell lines increase expression of a1h1, a2h1, and
a3h1 integrin heterodimers [26,27]—integrins that are absent
in high-grade NBL. These studies suggest that increased h1
integrin subunit expression correlates with increased NBL cell
adhesion and differentiation—properties of low-grade NBL.
Conversely, high-grade NBL cells have decreased integrin
expression, which potentially results in abnormal or loss of
integrin-mediated signaling and increased tumorigenesis.
The current study expands our investigations on the role of
integrin and IGF-IR expression and activation in human NBL
cells by examining NBL cell attachment to, and migration
across, ECM. In a panel of eight human NBL cell lines, less
tumorigenic adherent NBL cells express high levels of h1
integrin, whereas more tumorigenic, less adherent NBL cells
lack h1 integrin expression. Higher h1 integrin levels in less
tumorigenic cells are due to changes in protein turnover, not
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changes in transcription. h1 Integrin levels also correlate with
the degree of cell attachment to two ECM components:
fibronectin and collagen IV. Introduction of recombinant h1
integrin into less adherent NBL cell lines significantly
increases their attachment to fibronectin and collagen IV.
Inhibition of a5h1 integrin, which prevents attachment to
fibronectin and collagen IV, allows migration of nontumori-
genic NBL cells toward 10% calf serum (CS). In NBL cells
with high IGF-IR expression, migration is increased, which
likely results from the upregulation of the avh3 integrin. Our
results suggest that integrin and IGF-IR expression profiles
regulate NBL cell attachment to the ECM, which in turn
modifies NBL cell migration and may determine NBL meta-
static potential.
Materials and Methods
Materials
Falcon brand tissue culture supplies were purchased from
BD Biosciences (Bedford, MA). Chemicals were purchased
from Sigma-Aldrich Corp. (St. Louis, MO) or Fisher Scientific
(Pittsburgh, PA).
Cell Culture and Transfection
SHEP, SH-SY5Y, IMR32, and SK-N-AS cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Corporation, Carlsbad, CA) supplemented with
10% CS (Hyclone, Logan, UT). SH-IN, SK-N-BE-2-C, SK-N-
BE-2-M17, SMS-KCN-S, and SMS-KCN-69n cells obtained
from Dr. Valerie Castle’s laboratory at the University of
Michigan (Ann Arbor, MI) were grown in minimal essential
media (MEM) (Invitrogen Corporation) and F12 (1:1) supple-
mented with 10% fetal calf serum (FCS) (Hyclone). All NBL
cell lines were incubated at 37jC in a humidified atmosphere
with 10% CO2. Cells were routinely dissociated with trypsin–
EDTA (Invitrogen Corporation) for subculture.
SH-SY5Y and IMR32 cells were stably transfected with
the human h1 integrin GeneStorm clone RG000381 in a
pcDNA3.1-zeo vector, purchased from Invitrogen Corpora-
tion. The GeneStorm clones are sequenced for identity and
confirmed to produce protein before shipment. Each clone is
also tagged to allow for detection of the exogenous protein.
Transfections were performed with the pcDNA3.1/h1 integrin
vector or a control pcDNA3.1 vector using Lipofectamine
2000 following the manufacturer’s instructions (Invitrogen
Corporation). Cells were selected in DMEM containing 10%
CS and 250 mg/ml zeocin (Invitrogen Corporation) and
maintained in DMEM containing 10% CS and 100 mg/ml
zeocin. SHEP/IGF-IR cell clones [11] were maintained in
DMEM containing 10% CS and 250 mg/ml G418 (Invitrogen
Corporation).
Western Immunoblotting
Western blot analyses were performed as previously
described [8]. Cell lysates were collected using modified
RIPA buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1% sodium
deoxycholate) containing 10 mg/ml leupeptin, 10 mg/ml apro-
tonin, and 100 mg/ml PMSF. Five micrograms of protein was
loaded and subjected to sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE). After transfer to
nitrocellulose membranes (Hybond; Amersham Biosciences
Corp., Piscataway, NJ), the membranes were incubated
in a blocking solution composed of 5% Carnation nonfat
dry milk (Nestle USA, Inc., Solon, OH) dissolved in Tris-
buffered saline (TBS) containing 0.1% Tween-20 (TBST)
for 2 hours at room temperature or 4jC overnight. The
primary antibodies used were anti – h1 integrin
MAB1973Z, anti–a2 integrin MAB1950Z, anti–a3 integrin
MAB1952Z, anti–a4 integrin MAB16983Z, anti–a5 integ-
rin MAB1956Z, anti –av integrin MAB1953Z, anti –h1
integrin MAB2000, anti–h3 AB1932 (1:1000; all Chemicon
International, Inc., Temecula, CA), anti-V5 (1:1000; Invitro-
gen Corporation), and anti–glyceraldehyde-3-phosphate
dehydrogenase (1:10,000; Chemicon International, Inc.).
Blots were incubated with primary antibodies diluted in
blocking solution for 2 hours at room temperature or over-
night at 4jC. After extensive washing in TBST, blots were
incubated with horseradish peroxidase–conjugated goat
anti–mouse IgG or goat anti–rabbit IgG secondary antibody
(1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for
1 hour at room temperature. Blots were developed with the
Phototope-HRP Western Blot Detection Kit (Cell Signaling
Technology, Inc., Beverly, MA) according to the manufactur-
er’s instructions, and exposed to Hyperfilm-ECL film (Amer-
sham Biosciences Corp.). Blots shown are one of at least
three independent experiments performed.
Reverse Transcription–Polymerase Chain Reaction (RT-PCR)
RNA was isolated from six-well plates using the TRIzol
Reagent (Invitrogen Corporation) according to the manu-
facturer’s instructions. One microgram of RNA was used in
the Superscript First-Strand Synthesis System for RT-PCR
(Invitrogen Corporation) with random hexamers according
to the manufacturer’s instructions. cDNA was amplified
using the h1 integrin forward primer 5V-GATCAGTT-
CAGTTTGCTGTGTG-3V and the h1 integrin reverse primer
5V-TGTGCTAATGTAAGGCATCACAG-3V in a standard
PCR reaction (94jC for 2 minutes; 30 cycles of 94jC for
1 minute, 60jC for 1 minute, and 70jC for 30 seconds;
70jC for 10 minutes). Control primers for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were included
in the reactions. The GAPDH forward primer was 5V-
GTGAAGGTCGGAGTCAACG-3V and the GAPDH reverse
primer was 5VGGTGAAGACGCCAGTGGACTC-3V. The
cDNA fragments were separated on 1.5% agarose gels
and imaged with a Polaroid camera (Polaroid Corporation,
Waltham, MA).
Quantitative polymerase chain reaction (QPCR) was
performed using the Brilliant SYBR Green QPCR Master
Mix (Stratagene, La Jolla, CA). Briefly, fresh total RNA was
harvested as described for semiquantitative RT-PCR and
cDNA produced using the AMV reverse transcriptase kit
(Promega, Madison, WI) with oligo-dT primer, as per man-
ufacturer’s recommendations. The integrity of cDNA was
determined by conventional PCR for GAPDH. For QPCR,
aliquots of 2 ng of cDNA were combined with h1 integrin
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primers (150 mM each) and SYBR green master mix in a
final volume of 25 ml in a Smart Cycler Tube, 25 ml (Cepheid,
Sunnyvale, CA). Two different primer sets were used, with
each set designed to produce a 180-bp product. Primer
sequences are: set 1 forward, 5V-CCCTTGCACAAGTGAA-
CAGA-3V, set 1 reverse, 5V-ACATTCCTCCAGCCAATCAG-
3V; set 2 forward, 5V-CCCTTGCACAAGTGAACAGA-3V, set 2
reverse, 5V-CATTCCTCCAGCCAATCAGT-3V. QPCR was
carried out in a Smart Cycler (Cepheid) for 35 cycles. The
presence of final PCR products was confirmed by separation
on a 1.2% TAE agarose gel. Experiments were performed in
duplicate for each set of primers.
b1 Integrin Turnover
h1 Integrin turnover was studied according to the method
of Hotchin et al. [28]. NBL cell lines were serum-starved for
4 hours and then treated for 0, 2, 6, or 24 hours with 5 mg/ml
cycloheximide (Sigma-Aldrich Corp.) [12]. Cell lysates were
collected for SDS-PAGE and Western immunoblotting as
described. h1 Integrin levels were measured with computer-
assisted densitometry using NIH Image as previously de-
scribed [29]. h1 Integrin turnover rates were calculated by
plotting the percentage control of optical density (at time 0) of
h1 integrin against time.
Pulse-Chase Experiments
Pulse-chase experiments were performed using the
method of Hotchin et al. [28]. NBL cell lines were serum-
starved for 4 hours and then cultured in DMEM lacking
cysteine and methionine (Invitrogen Corporation) for 1 hour.
Cells were pulsed for 1 hour with 50 mCi/ml [35S]cysteine and
[35S]methionine (Pro-mix L[35S] in vitro cell labeling mix;
Amersham Biosciences Corp). Medium containing DMEM
with 10% CS was replaced and the cells were incubated for
0, 2, 6, or 24 hours. Cell lysates were collected in modified
RIPA buffer. Four hundred micrograms of protein was pre-
cleared with 30 ml of protein A/G agarose (Santa Cruz
Biotechnology, Inc.) and immunoprecipitated with 2 mg of
anti–h1 integrin MAB 2000 antibody (Chemicon Internation-
al, Inc.) overnight at 4jC with end-over-end rotation. Thirty
microliters of protein A/G agarose was added to the lysates
for 4 to 5 hours at 4jC with end-over-end rotation. After
extensive washing in modified RIPA buffer, 30 ml of 2  SDS
sample buffer (20 mM Tris, pH 8.0, 2 mM EDTA, 2% SDS,
20 mM dithiothreitol, 0.02% bromophenol blue, and 4%
glycerol) was added to the beads, which were boiled and
subjected to SDS-PAGE on 4% to 20% gradient gels (Bio-
Rad Laboratories, Hercules, CA). The gels were fixed in
50% methanol with 10% acetic acid for 30 minutes at 4jC
and then placed in gel-drying solution (7% methanol, 7%
acetic acid, and 1% glycerol) for 5 minutes. The gels were
dried for 90 minutes at 80jC and then exposed to X-OMAT
AR film (Eastman Kodak Company, Rochester, NY).
Attachment Assays
Cells were dissociated in trypsin–EDTA for 5 minutes,
and then centrifuged for 5 minutes at 3000 rpm (18771g) in a
Sorvall RT6000B (Kendro Laboratory Products, Asheville,
NC) centrifuge in the presence of 2% CS to inactivate the
trypsin. Cells were then rinsed twice in Hank’s balanced salt
solution (HBSS) lacking calcium and magnesium (BioWhit-
taker, Walkersville, MD) and resuspended in DMEM. A total
of 6104 cells was plated in triplicate on fibronectin, collagen
IV, vitronectin, or bovine serum albumin (BSA) in DMEMwith
and without 25 mg/ml anti–a5h1 integrin–blocking antibody
MAB1969 (Chemicon International, Inc.) using the CytoMa-
trix Screen Kit (Chemicon International, Inc.) according to
the manufacturer’s instructions and incubated at 37jC, 10%
CO2 for 1 hour. Cells were rinsed three times with phos-
phate-buffered saline (PBS) containing calcium and magne-
sium and stained for 5 minutes with 0.2% crystal violet
dissolved in 10% ethanol. After two washes with PBS (no
calcium or magnesium), crystal violet was eluted with 0.1 M
NaH2PO4 containing 50% ethanol for 15 minutes and the
optical densities were measured in a Multiskan Ascent pla-
tereader (LabSystems, Helsinki, Finland) at 540 nm.
To verify that the cell types did not absorb the crystal vio-
let dye differently, a standard curve was generated for each
cell line. Between 1103 and 7.5104 cells were plated in
96-well plastic tissue culture plates and centrifuged for 5
minutes. Cells were then stained with crystal violet and
rinsed, and the dye was eluted. Average optical densities
were calculated and plotted against cell numbers.
Migration Assays
Cells were dissociated in trypsin–EDTA for 5 minutes,
and then centrifuged for 5 minutes at 3000 rpm (1877g) in a
Sorvall RT6000B centrifuge in the presence of 2% CS to
inactivate the trypsin. Cells were then rinsed twice in HBSS
and resuspended in DMEM. Migration assays were per-
formed by plating 6104 cells in 100 ml of DMEM with or
without 25 mg/ml a5h1 integrin–blocking antibody in triplicate
in Corning 6.5-mm transwells with 3-mm pores (Fisher Sci-
entific International, Inc., Hampton, NH). Ten percent CS in
DMEMwas added to the bottom well to stimulate migration of
NBL cells through the transwell membrane. Cells were
incubated for 18 hours at 37jC and 10% CO2. Cells on the
inside of the transwell were removed by gently swabbing with
a cotton swab. Cells that had migrated through the transwell
were stained with 0.2% crystal violet in 10% ethanol for 5
minutes, rinsed with PBS, and eluted with 0.1 M NaH2PO4
containing 50% ethanol for 15 minutes. Optical densities
were measured on a Multiskan Ascent platereader (LabSys-
tems) at 540 nm.
avb3 Integrin Surface Expression and Binding Assay
avh3 Integrin expression was analyzed by Western im-
munoblotting (for total protein levels) and flow cytometry (for
cell surface expression). For Western immunoblotting, cells
were harvested and run as described above, then immuno-
blotted using an anti–avh3 antibody. For flow cytometry,
cells were harvested with 1 mM EDTA and incubated with
anti–avh3 (MAB1976F; Chemicon International, Inc.), then
fluorescein isothiocyanate (FITC)–conjugated anti–mouse
antibody (Invitrogen Corporation) and fluorescence were
measured using a flow cytometer [30].
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To analyze functional binding through the avh3 integrin,
cellular adhesion of SHEP/vector and SHEP/IGF-IR cells
mediated by avh3 integrin was measured using an Integrin-
Mediated Cell Adhesion Kit from Chemicon International,
Inc. Analysis was performed as per manufacturer’s protocol.
Briefly, a cell suspension containing 350,000 cells/ml in PBS
detached from the plate using 5 mM EDTA was prepared.
One hundred microliters of cell suspension was added to the
control plate and the 96-well capture plate. The capture plate
contained a monoclonal antibody against human avh3 immo-
bilized to the plate with goat anti–mouse antibody. Cells
were incubated on the plate for 2 hours, then rinsed with
PBS containing 1 mM Ca2+/Mg2+. After rinsing, cells were
stained for 5 minutes using the provided Cell Stain Solution,
rinsed five times, and air-dried. Wells were then incubated in
the provided extraction buffer for 5 minutes, and absorbance
was read at a wavelength of 560 nm using a LabSystems
Fluoroskan Ascent FL fluorimeter (LabSystems, Franklin,
MA). Results are presented as the mean optical density ±
SEM relative to control.
Results
Integrin Profile in Human NBL Cell Lines
h1 Integrin expression in eight NBL cell lines was com-
pared with known NBL cell phenotypes. Human NBL tumors
contain several morphologically distinct cell types, and these
have been subcloned into cell lines with unique character-
istics [31]. S-type cells (SHEP cells) are highly substrate-
adherent, grow in monolayer cultures, do not form tumors in
nude mice, and have a finite lifespan [31]. N-type cells (SH-
SY5Y and IMR32 cells) exhibit small, rounded cell bodies,
with many lamellipodia and neurites extending from the
soma. N-type cells are tumorigenic in nude mice and have
an infinite lifespan [31]. We chose to test two S-type lines,
two I-type lines (intermediate morphology and tumorigenic
properties) [31], and four N-type lines. S-type (SHEP and
SMS-KCN-S) and I-type (SH-IN and SKN-BE-2-C) NBL cells
have high h1 integrin levels, whereas N-type (SH-SY5Y,
IMR32, SK-N-BE-2-M17, and SMS-KCN-69n) cell lines have
low levels of h1 integrin (Figure 1A).
We additionally characterized the expression of a1, a2,
a3, a4, a5, and av integrin in SHEP, SH-SY5Y, and IMR32
human NBL cell lines (Figure 1B). SHEP cells are the least
tumorigenic S-type cells [31] and express the highest levels
of the a3, a5, and h1 integrin subunits. The SH-SY5Y and
IMR32 cells are the most tumorigenic NBL cell lines [31,32]
used in this study, and they express very little a2 and h1
integrin and moderate amounts of a3 and a5 integrin (Figure
1B). No correlation between the expression of the remain-
ing integrin subunits examined (a1, a4, and av) and known
relative tumorigenicities [31,32] was observed (Figure 1B).
Upregulated b1 Integrin in SHEP Cells Is Due to Changes in
Turnover of Protein
The observed differences in h1 integrin protein levels
among the NBL cell lines may be due to either increased
transcription or changes in h1 integrin protein turnover.
SHEP (S-type) and SH-SY5Y (N-type) cells are derived from
the same parental NBL tumor [31]. We examined the differ-
ences in h1 integrin expression in these paired cell lines, as
well as in another unrelated tumorigenic N-type cell line,
IMR32 cells. mRNA levels of h1 integrin, measured using
semiquantitative RT-PCR, were unchanged among SHEP,
SH-SY5Y, and IMR32 cells, suggesting that transcription of
the h1 integrin gene is not different among these cell lines
(Figure 2A). To confirm the semiquantitative PCR results, we
performed quantitative, real-time PCR using two sets of
primers to two different portions of the h1 integrin molecule.
Fluorescence, indicating the amount of h1 integrin transcript
formed, was similar for all three cell lines, amplified above
background at 25 cycles and increasing to saturated fluo-
rescence over a similar number of cycles (Figure 2B).
Therefore, the differences in h1 integrin protein levels
detected are not due to differences in transcription in the
three NBL cell lines.
We used two methods to ascertain the turnover of h1
integrin in SHEP, SH-SY5Y, and IMR32 cells. Pulse-chase
Figure 1. Integrin expression in NBL cell lines. (A) b1 Integrin Western blot of
SHEP (S-type), SMS-KCN-S (S-type), SH-SY5Y (N-type), IMR32 (N-type),
SKN-BE-2-M17 (N-type), SMS-KCN-69n (N-type), SH-IN (I-type), and SKN-
BE-2-C (I-type) NBL cell lines. I-type cells are intermediate in morphology and
tumorigenic characteristics between S-type and N-type. (B) Western blots of
SHEP, SH-SY5Y, and IMR32 cells. a1 = 150 kDa; a2 = 160 kDa; a3 = 150 kDa;
a4 = 150 kDa; a5 = 150 kDa; av = 125 kDa; b1 = 130 kDa. Blots are one
representative example of three or more separate experiments.
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experiments were performed to measure the half-life of the
h1 integrin protein. h1 Integrin protein appears within 2 hours
in SHEP cells and lasts at least 24 hours (Figure 2C).
However, h1 integrin was not detectable in SH-SY5Y or
IMR32 cells within 24 hours. Next, cells were treated with
5 mg/ml cycloheximide to abolish protein synthesis and
examine h1 integrin protein degradation. Our laboratory
and others have previously demonstrated that this concen-
tration of cycloheximide is sufficient to block 95% of protein
synthesis within 1 to 3 hours in NBL cells [12,28]. Western
blots of h1 integrin show that expression does not change
within 24 hours (Figure 2D) in SHEP cells, but that its
expression decreases between 2 and 24 hours in SH-
SY5Y and IMR32 cells following cycloheximide treatment.
In fact, h1 integrin levels fall to 40% of control levels in SH-
SY5Y and IMR32 cells, while only decreasing to 83% by 24
hours in SHEP cells (Figure 2E ). These data indicate in-
creased degradation of h1 integrin protein in N-type cells,
leading to decreased protein half-life.
b1 Integrin Expression Increases Attachment to Fibronectin
and Collagen IV
Because integrins are involved in cell–ECM interactions,
we next examined the effect of h1 integrin levels on adhesion
Figure 2. Differences in b1 integrin expression are due to decreased turnover in SHEP cells. (A) Semiquantitative RT-PCR of b1 integrin (top band) and GAPDH
(bottom band) in SHEP, SH-SY5Y, and IMR32 cells. mRNA levels remain unchanged among the different cell lines. The agarose gel shown is one representative
example of four separate experiments. (B) Quantitative, real-time PCR of b1 integrin in SHEP, SH-SY5Y, and IMR32 cells. (C) Pulse-chase labeling of nascent b1
integrin protein in SHEP, SH-SY5Y, and IMR32 cells at 0, 2, 6, and 24 hours. (D) Western blot of b1 integrin after treatment with 5 g/ml cycloheximide for 0, 2, 6,
and 24 hours to inhibit protein synthesis in SHEP, SH-SY5Y, and IMR32 cells. Percent control of optical density for each cell line is plotted against time in the graph.
Blot and graph shown are one representative example from four separate experiments. (E) Table representing the results from all four experiments performed in
(D). Results are expressed as optical density ± SEM.
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in S-type and N-type NBL cell lines. The a5h1 integrin het-
erodimer is one h1-containing integrin receptor that binds to
fibronectin, whereas the a1h1, a2h1, a3h1, and avh1 integrin
heterodimers all bind to collagen IV [33]. Vitronectin predom-
inantly binds to avh3 integrin, not h1 heterodimers [33], and
was therefore used as a control. SHEP cells adhere more
strongly to fibronectin and collagen IV than to vitronectin
(Figure 3A; P = .007 and P < .0001, respectively). SH-SY5Y
cells and IMR32 cells also adhere to fibronectin and collagen
IV, but with less affinity than SHEP cells (Figure 3A; SH-
SY5Y and IMR32: P = .007 and P = .003, respectively, for
fibronectin compared with SHEP cells on fibronectin). Given
the strong attachment of NBL cells to fibronectin, we next
assayed attachment in the presence and absence of an a5h1
integrin–blocking antibody, as this integrin is the predomi-
nant binding partner for fibronectin (Figure 3A). The specific
antibody used block binding of a5h1 integrin to fibronectin by
inducing a conformational change in the a5h1 integrin heter-
odimer [34]. The a5h1 integrin–blocking antibody decreased
attachment of SHEP cells to fibronectin by about 75%
(P = .002), suggesting that SHEP NBL cell attachment to
fibronectin was indeed primarily through the a5h1 integrin
receptor. However, SH-SY5Y and IMR32 NBL cell attach-
ment to fibronectin was not through the a5h1 integrin re-
ceptor, as the a5h1 integrin–blocking antibody did not
affect attachment of these cells to fibronectin. Additionally,
SH-SY5Y cells and IMR32 cells adhered to vitronectin sig-
nificantly more than SHEP cells (P = .0001 and P = .003,
respectively). The differences in attachment among the three
cell lines were not due to variations in the cells’ ability to bind
the crystal violet stain because standard curves comparing
cell number with the optical density of eluted crystal violet
overlapped (Figure 3B). These results suggest that h1 integ-
rin (especially the a5h1 integrin heterodimer), is important
in attachment of less tumorigenic S-type cells to fibronectin
and that N-type NBL cell lines expressing decreased
amounts of h1 integrin are less adhered to fibronectin.
Overexpression of b1 Integrin in N-Type NBL Cell Lines
Increases Attachment
Our hypothesis is that h1 integrin expression in NBL cells
decreases cell migration through increased cell attachment,
leading to decreased tumorigenic potential. We therefore
stably transfected SH-SY5Y and IMR32 cells with recombi-
nant human h1 integrin containing an N-terminal V5 epitope
tag or with empty pcDNA3.1 zeo vector and investigated
attachment. Both N-type NBL cell lines express recombinant
h1 integrin, although the IMR32 cells express more than the
SH-SY5Y cells (Figure 4A, upper blot). Moreover, the IMR32
cells overexpress the total amount of h1 integrin (recombi-
nant and endogenous), whereas the SH-SY5Y cells do not
(Figure 4A, bottom blot). h1 Integrin–transfected N-type cell
lines grow more slowly than the vector-transfected controls
(our observations). In fact, stable clones expressing high
levels of recombinant h1 integrin cease cell division and die.
These results were similar to those obtained when SHEP
cells were stably transfected with h1 integrin (our unpub-
lished data). Introduction of recombinant h1 integrin in both
Figure 3. Attachment of NBL cell lines to ECM proteins. (A) SHEP, SH-SY5Y,
and IMR32 cells were allowed to adhere to fibronectin, collagen IV, or vitro-
nectin for 1 hour in the presence or absence of the a5b1-blocking antibody,
and then stained with crystal violet. Optical density at 540 nm is plotted
against cell line and condition. Error bars show SEM. The graphs are one
representative example of two separate experiments, plated in triplicate. (B)
SHEP, SH-SY5Y, and IMR32 cells absorb the crystal violet stain equally.
Optical density is plated against the number of cells. Error bars show SEM.
The graphs are one representative example of two separate experiments,
plated in triplicate.
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N-type cell lines increases their attachment to fibronectin
(Figure 4B; SH-SY5Y, P = .02; IMR32, P = .007), whereas
there is a trend to increase attachment on collagen IV.
Although the untransfected N-type NBL cell lines attach
relatively equally to fibronectin (Figure 3A), the difference
in the amount of recombinant h1 integrin expressed corre-
lates with the amount of attachment on fibronectin and
collagen IV. SH-SY5Y cells express less recombinant h1
integrin than IMR32 cells, and the transfected SH-SY5Y cells
attach less to fibronectin than the transfected IMR32 cells.
The a5b1 Integrin–Blocking Antibody and Decreased b1
Integrin Expression Promote Migration in SHEP Cells
Migration refers to the ability of a cell to move in a specific
direction, usually toward a chemoattractant or away from a
chemorepellent. SHEP cell movement toward 10% CS
was examined to investigate the role of h1 in cell migration.
SHEP cells were plated in a transwell membrane and
allowed to migrate toward a solution of DMEM with 10%
CS for 18 hours. Addition of the a5h1 integrin–blocking anti-
body increased migration of SHEP cells toward the 10% CS
(Figure 5). These data imply that the a5h1 integrin–blocking
antibody, which causes SHEP cells to adhere less to fibro-
nectin, also allows them to move toward the chemoattrac-
tant. Intact h1 integrin signaling in the control-treated SHEP
cells causes them to adhere securely to the ECM, thus
impeding their migration toward 10% CS.
Our laboratory has previously shown that NBL cells with
increased tumorigenic potential express higher levels of the
IGF-IR [18,19]. This increase in IGF-IR levels promotes NBL
cell proliferation, survival, anchorage-independent growth,
invasion, and tumor formation in nude mice [11,14,18]. In the
current study, we find that SHEP cells expressing increased
IGF-IR have decreased expression of h1 integrin compared
with control SHEP cells (Figure 6A). SHEP/IGF-IR cells are
significantly more migratory than control cells with or without
IGF-I ligand present (Figure 6B; P < .01), suggesting that
increased IGF-IR expression alone is enough to increase
migratory potential. Both cell types respond to IGF-I as a
chemoattractant in a dose-dependent fashion, with signifi-
cantly increased migration in the presence of 10 nM IGF-I
(Figure 6B; SHEP/vector cells, P = .02; SHEP/IGF-IR cells,
P = .0062). These data support our hypothesis that
decreases in h1 integrin protein expression promote a more
migratory phenotype in human NBL cell lines.
avb3 Integrin Enhances NBL Cell Migration
Recent reports suggest that avh3 integrin occupancy is
required for IGF-IR–mediated migration [35–38]. Given the
increase in IGF-IR in tumorigenic NBL cells, we investigated
avh3 integrin expression in SHEP cells overexpressing the
IGF-IR. In SHEP/IGF-IR cells, h3 integrin protein levels are
increased—both overall expression levels (Figure 7A, left
panel ) and expression on the cell surface (Figure 7B). To
confirm that yvh
ˆ
3 expression is also increased in NBL cells
endogenously expressing higher IGF-IR levels, Western
immunoblotting for aˆ3 integrin was performed in SHEP,
SH-SY5Y, and IMR32 cells. h3 Integrin levels are low in
SHEP cells, but are increased in SH-SY5Y and IMR32 cells
(Figure 7A, right panel ). Cell binding to immobilized avh3
integrin antibody is also increased in SHEP/IGF-IR cells,
suggesting that functional avh3 is increased (Figure 7C).
These data suggest that the high levels of migration in
SHEP/IGF-IR cells may be, in part, due to the expression
of avh3 integrin.
Finally, to further support that the avh3 integrin expressed
in the SHEP/IGF-IR cells is functional, these cells were
plated in an attachment assay. Attachment to vitronectin
was tested, as this is the primary ECM substrate for avh3.
SHEP cell binding to vitronectin increases by nearly 10-fold
when IGF-IR is overexpressed (Figure 7D). Interestingly, the
N-cells used in the first part of this study, which express
higher levels of endogenous IGF-IR (Figure 1A) and yvh3
(Figure 7A), also attach more strongly to vitronectin (Figure
3A). Therefore, results of this study, coupled with previous
Figure 4. Recombinant b1 integrin expression in N-type NBL cell lines. (A)
Western blot of recombinant b1 integrin (anti-V5) (top blot) and total b1 integrin
(bottom blot) in SHEP, SH-SY5Y, SH-SY5Y pcDNA3.1 zeo, SH-SY5Y b1
integrin, IMR32, IMR32 pcDNA3.1 zeo, and IMR32 b1 integrin. Blots are one
representative example of three separate experiments. (B) Attachment assay
of b1 integrin-transfected SH-SY5Y and IMR32 cells on fibronectin and
collagen IV. Optical density at 540 nm is plotted against cell line and
condition. Error bars show SEM. The graphs are one representative example
of two separate experiments, plated in triplicate.
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reports from our laboratory, indicate that highly tumorigenic
NBL cells express increased IGF-IR, decreased h1 integrin,
and increased yvh3, leading to decreased attachment to
their primary ECM and increased migration.
Discussion
Integrins and growth factors both play a role in tumor
progression and are involved in tumor cell growth, migration,
and invasion, ultimately leading to metastasis [39]. Our
laboratory is interested in how these two classes of proteins
interact to control NBL migration and invasion. In the current
study, we compared the tumorigenicity of NBL cell lines with
integrin expression levels. The most striking result demon-
strates a near loss of h1 integrin expression in highly tumor-
igenic NBL cells. SHEP cells, the least tumorigenic of the
NBL cell lines tested [31,32], have the highest h1 integrin
expression (Figure 1). Conversely, SH-SY5Y and IMR32
cells are the most tumorigenic NBL cell lines [31,32], and
express the least h1 integrin (Figure 1). Our expression data
support previous flow-activated cell sorting analysis data
showing that a5h1 integrin is expressed in S-type, but not
N-type, NBL cell lines [40]. The most common genetic
anomaly detected in NBL tumors is amplification of the
MYCN gene [41], which results in highly aggressive tumors.
We and others have shown that expression of N-myc, the
gene product of MYCN, in NBL cell lines decreases h1
integrin expression and increases tumorigenicity [25,42].
Furthermore, highly malignant NBL tumors with MYCN
Figure 5. Migration of SHEP cells. SHEP cells were plated in duplicate in
DMEM on transwells in the presence or absence of the a5b1 integrin–
blocking antibody and allowed to migrate toward 10% CS forx 18 hours.
Optical density is plotted against condition. Error bars show SEM.
Figure 6. SHEP/IGF-IR cells downregulate b1 integrin. (A) Western blot of b1 integrin in SHEP/vector and SHEP/IGF-IR cells. (B) SHEP/vector and SHEP/IGF-IR
cells were plated on uncoated 3-m transwell filters in DMEM + 0.1% serum until cells attached. Medium was then changed to DMEM in the upper chamber and to
DMEM + 0, 1, or 10 nM IGF-I in the lower chamber. Cells were allowed to migrate for 24 hours, nonmigrating cells were removed from the upper surface of the
membrane, migrating cells on the bottom surface were stained, and quantitation of the experiment was performed as previously described [18]. Values are
represented as mean ± SEM for each condition. An asterisk (*) represents statistical significance (P < .02) compared to 0 nM control, and a delta (D) represents
statistical significance (P < .01) compared to SHEP/vector control.
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amplification do not express most h1 integrin heterodimers
[24]. These results suggest that there may be an inverse
relationship between N-myc overexpression and loss of h1
integrin expression, and that high h1 integrin expression may
promote a less aggressive phenotype in NBL cell lines.
Changes in h1 integrin may be due to differences in
transcription, translation, or protein turnover. Our data sug-
gest that NBL cell lines have similar levels of h1 integrin
mRNA expression, but differences in h1 integrin protein
turnover (Figure 2). The mechanism for increased h1 integrin
turnover in N-type cells is unknown. In fibroblasts, integrins
are continually synthesized, processed, and transported to
the cell surface. Once on the cell surface, h1 integrin is
rapidly internalized and degraded within lysosomes [43].
Alternatively, h1 integrin may be posttranslationally modified,
leading to its degradation in less adherent cells. For instance,
many proteins become targets for the 26S proteasome when
they are phosphorylated. As cytoplasmic h1 integrin is phos-
phorylated and h1 integrin localized to focal adhesions is
dephosphorylated [44], h1 integrin not localized at the cell
membrane may be targeted to the 26S proteasome for
degradation. Another possibility lies in the idea that N-cells
may synthesize but not express h1 integrin. For example,
cells grown in agar (i.e., anchorage-independent conditions)
are able to synthesize h1 integrin but do not express it at
the cell surface [43]. Our results do suggest that a positive
feedback cycle may exist between NBL attachment and h1
integrin expression. Decreased adhesion in N-type cells may
lower h1 integrin levels, preventing attachment to the ECM.
This decreased attachment to ECM then further lowers h1
integrin levels, promoting a feed-forward cycle that contrib-
utes to the malignant properties of high-grade NBL tumors.
A functional role for decreased h1 integrin in NBL cells
may be decreased attachment to matrix, allowing increased
migration. S-type cells have high levels of h1 integrin and
attach well to fibronectin and collagen IV (Figure 3). N-type
cells, in contrast, express low levels of h1 integrin and are
only loosely attached to fibronectin and collagen IV. Addi-
tionally, blockade of a5h1 integrin using a blocking antibody
interferes with attachment of S-type cells, but not N-type
cells, to fibronectin, indicating that a5h1 integrin is important
in S-type cell attachment, but not N-type cell attachment, to
the ECM (Figure 3). Lastly, introduction of recombinant h1
integrin into N-type cells increased their attachment to
fibronectin (Figure 4). h1 Integrin is involved in ECM attach-
ment in other tumors as well, including breast carcinoma
[45], invasive melanoma cells [46], and chronic myeloge-
nous leukemia [47]. In some breast cancers, a decrease in
a2h1 integrin causes a loss of contact with myoepithelial
cells and the basement membrane, which is accompanied
by increased cell proliferation, thus initiating tumor growth
and metastasis [45]. We therefore propose that decreased
attachment and increased migration in tumorigenic NBL
cells through downregulation of h1 integrin may be factors
that promote metastasis. Blocking a5h1 integrin binding to
the ECM and downregulation of h1 integrin cause increased
migration in SHEP cells (Figures 5 and 6). These results
indicate that the low rate of migration in untreated SHEP
cells is related to strong attachment to the ECM by a5h1
integrins (Figures 5 and 6). Similarly, in invasive melanoma
tumors, migration and migration-associated ECM reorgani-
zation are also dependent on the strength of h1 integrin
adhesion [46].
In addition to integrins, growth factors also regulate tumor
cell migration, invasion, and metastasis. We previously
demonstrated that highly tumorigenic NBL cells express
increased levels of the IGF-IR [19,48]. In fact, increased
expression of IGF system components is present in a wide
range of human cancers [49], including lung, breast, thyroid,
prostate, glioblastoma, rhabdomyosarcoma, leukemia, and
NBL (reviewed in Ref. [50]). In the current study, SHEP cells,
with low IGF-IR, migrate little, although migration increases
slightly with addition of IGF-I. SHEP cells overexpressing the
IGF-IR have decreased h1 integrin expression and signifi-
cantly more baseline and IGF-I–stimulated migration. IGF-
IR activation enhances migration in several other cell types,
including epithelial cells [51,52], cancer cells [51,53,54], and
smooth muscle cells [36,37,51]. Furthermore, bone contains
high levels of IGF-I [55,56]. NBL metastasizes to the bone,
and the presence of bone metastasis in children indicates a
stage IV tumor with poor prognosis, resulting in a survival
rate of less than 7% [1]. Therefore, IGF-IR–expressing NBL
tumor cells with an increased migratory capability respond to
IGF-I as a chemoattractant, which potentially explains why
bone is the primary site of NBL metastases [55,57].
Figure 7. IGF-IR overexpression increases avb3 integrin in SHEP NBL cells.
(A) SHEP/vector, SHEP/IGF-IR, SHEP, SH-SY5Y, and IMR32 cells were
grown to near confluence and whole cell lysates were collected. Lysates were
run on a SDS-PAGE gel and Western-immunoblotted for the b3 integrin
subunit using a b3 integrin polyclonal antibody. (B) avb3 Integrin surface
expression measured by flow cytometry. The average relative log fluores-
cence for SHEP/vector is 17.5 compared with 50.1 for SHEP/IGF-IR. (C) avb3
Integrin binding assay. Error bars show SEM (P = .029). (D) SHEP/vector and
SHEP/IGF-IR cells were plated on vitronectin. Cells were allowed to attach
for 2 hours and rinsed, then adherent cells were stained and read on a
fluorimeter [59] (P = .002).
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Recent evidence suggests that avh3 integrin occupancy is
required for IGF-IR–mediated migration [35–38]. In the
current study, IGF-IR overexpression increases the levels
of functional avh3. Increased avh3 promotes attachment to
vitronectin, one of the ECM components of bone. In smooth
muscle cells, IGF-I–mediated migration only occurs if the
avh3 integrin is bound to ECM, and unoccupied integrin
heterodimers or mutated h3 subunits (but not h1) block
IGF-IR–mediated migration [35–38]. In NBL tumors, ex-
pression of only one integrin, avh3, is increased in undiffer-
entiated NBL and, when overexpressed, results in a highly
invasive metastatic phenotype [58]. Taken together, these
studies, coupled with our results, suggest that increases in
avh3 integrin may enhance IGF-IR–mediated NBL cell mi-
gration and increase NBL cell attachment to bone ECM
components, thereby promoting metastasis.
In summary, less tumorigenic S-type NBL cells have high
h1 integrin expression, are securely attached to the ECM
through h1 integrin interactions, have low IGF-IR levels and
avh3 expression, and are less migratory. N-type NBL cells
are more tumorigenic, have low h1 integrin expression, are
loosely attached to the ECM, have increased IGF-IR and
avh3, and are more migratory. The differences in h1 integrin
expression between the N-type and S-type NBL cell lines are
due to variations in h1 integrin protein turnover. Decreased
h1 integrin levels, coupled with increased IGF-IR and avh3
integrin expression, may therefore represent one mecha-
nism promoting increased NBL metastasis. Future studies
will fully explore the interaction between the IGF-IR and avh3
integrin during NBL cell migration.
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